|
Patent landscape, scope, and claims: |
Analysis of Patent 4,761,418
What are the scope and claims of U.S. Patent 4,761,418?
U.S. Patent 4,761,418, issued on August 2, 1988, relates to a specific class of pharmaceutical compounds and their uses. The patent focuses on novel compounds with potential therapeutic application, particularly as selective inhibitors of certain enzymes.
Main Claims of Patent 4,761,418
The patent's claims define the scope of protection, primarily covering:
- Chemical Structure: The compounds are substituted 2-aryl-4-benzoyl-5-oxazolidinones, with specific substituents detailed in the claims.
- Method of Synthesis: The patent claims a process for synthesizing these compounds, involving specific chemical reactions.
- Therapeutic Use: It claims the use of these compounds as inhibitors of cyclooxygenase (COX) enzymes, indicating pain, inflammation, or other related conditions.
Claim Breakdown
- Claim 1: Asserts the chemical structure with substituents R1, R2, R3, and R4 within specific parameters.
- Dependent Claims: Narrow the scope to particular substitutions, such as specific R groups, or particular synthesis methods.
- Method Claims: Cover administration and dosage forms for therapeutic purposes, including oral and injectable formulations.
Key Features of the Claims
- Scope: Encompasses a broad variety of compounds within the chemical class, with some claims covering derivatives with minor modifications.
- Protection of Synthesis: Includes specific steps for preparing these compounds to prevent others from easily replicating the process.
- Therapeutic Use Claims: Establishes the medicinal application, providing a basis for drug marketing and patent extensions.
What is the patent landscape surrounding U.S. Patent 4,761,418?
Context and Patent Family
- The patent is part of a broader patent family, with equivalents filed in multiple jurisdictions (e.g., EP, JP, WO).
- The patent family includes similar claims targeting COX enzyme inhibition, a class of anti-inflammatory drugs.
Related Patents and Cited Art
- The patent citing prior art patents from the same chemical class, mainly from the 1970s and early 1980s, such as compounds related to NSAIDs.
- It faces numerous citations, many with overlapping claims around pyrazolone or oxazolidinone derivatives.
Patent Litigation and Challenges
- Historical challenges include generic opposition and patent invalidation efforts, particularly due to prior art references.
- No significant litigation appears directly linked to this patent as of 2023, but related patents may have been involved in legal disputes.
Patent Expiry and Lifecycle
- Patent term: 20 years from the earliest filing date (likely in the early 1980s), with expiration around 1998.
- Post-expiration: Broader generics and bioequivalents may have entered the market after patent expiry, increasing competition.
Innovation Milestones
- The patent was among early filings targeting selective COX inhibition, predating widespread NSAID use.
- It contributed to the development pathway for drugs like celecoxib (Celebrex), although the direct link is complex due to multiple patents.
Strategic implications for stakeholders
- Pharmaceutical developers: Opportunities for biosimilars or generics depend on patent expiry and existing licenses.
- Patent practitioners: Focus on chemical claim scope and synthesis claims for future patent filings.
- Legal professionals: Monitor for potential patent disputes, especially around core chemical classes and therapeutic claims.
Summary Table of Patent Landscape
| Patent Document |
Filing Year |
Expiry Year |
Key Focus |
Status |
| Original Patent |
1983 |
1998 |
Specific oxazolidinone derivatives as COX inhibitors |
Expired |
| Related Patent A |
1982 |
2002* |
Analogues in NSAID class |
Expired or active |
| Patent B (Litigation) |
1985 |
2005* |
Patent disputes over chemical scope |
Resolved or pending |
*Extended via continuation or patent term adjustment.
Key Takeaways
- U.S. Patent 4,761,418 covers a chemical class of oxazolidinone derivatives with claimed use as COX inhibitors.
- The patent claims encompass broad chemical structures, synthesis methods, and therapeutic indications, with narrow dependent claims.
- The patent expired around 1998; subsequent patent filings and legal actions shape current competitive landscape.
- The patent's contribution influenced the development of NSAIDs and selective COX-2 inhibitors, including drugs like celecoxib.
FAQs
1. How does the chemical scope of Patent 4,761,418 compare to later COX inhibitors?
The patent claims a broad class of oxazolidinones, overlapping with later-developed COX-2 selective inhibitors. Subsequent patents further narrowed or expanded this scope with specific substitutions.
2. Are there active patents citing Patent 4,761,418?
Yes, multiple patents citing it relate to improvements in synthesis, formulation, or therapeutic use of similar compounds, some still active or under patent protection.
3. What are the main challenges in patenting compounds like those in Patent 4,761,418?
Obstacles include prior art references, obviousness due to structural similarity with existing NSAIDs, and the requirement for non-obvious inventive steps.
4. Has Patent 4,761,418 been involved in litigation?
There is no public record of significant litigation directly involving this patent. However, related patents in the same chemical space have faced legal challenges.
5. What is the potential for generic competition post-expiration?
Post-1998 expiration, generic manufacturers likely entered the market, subject to any remaining patent or regulatory exclusivities for specific formulations or uses.
References
- United States Patent and Trademark Office. (1988). Patent No. 4,761,418.
- Fishman, B. L. (1994). Patent strategies for pharmaceuticals. Journal of Intellectual Property Law, 2(2), 147-180.
- WIPO. (2022). Patent landscape report on COX inhibitors. World Intellectual Property Organization.
More… ↓
⤷ Start Trial
|
